Recon: Roche to market $50 flu pill to US cash buyers; Praxis surges on positive results from shaking disorder trials
ReconJason Scott
Biologics/ biosimilars/ vaccinesEuropeGlobalMedical DevicesNorth AmericaPharmaceuticalsRegulatory Intelligence/PolicyUnited States